FDAsafety guidance72% confidence
Training Course: Achieving Data Quality and Integrity in Maximum Containment Laboratories
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as opioid treatment pharma companies.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Addiction · Opioids
- Sub-indication
- Pain
Related signal: University of Missouri-Columbia Launches Naloxone Training Initiative to Combat Opioid Overdoses